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Abstract 
Cardiovascular disease currently accounts for over 800,000 American deaths per year, serving as 
the leading cause of death nationwide. Pulse Wave Velocity (PWV) lends us information on 
cardiovascular health and is now considered a gold standard for measuring arterial health in 
adults. Deleterious changes in arterial compliance, in addition to a poor body composition, have 
been shown to be early risk factors in the onset of cardiopulmonary and arterial disease. 
The Withings Body Cardio Scale has been marketed to the general population for its ability to 
measure PWV and body composition in the home, however, there are no data that demonstrate 
the accuracy of this technology. PURPOSE The aim of this study was to determine the accuracy 
and reproducibility of the PWV and body composition features within the Withings Body Cardio 
(Withings, Issy-les-Moulineaux, France) in comparison to the gold standard in 
applanation tonometry (SphygmoCor, AtCor Medical, Itasca, Illinois, USA) and body 
composition analysis (BodPod, Life Measurement, Inc., Concord, CA, USA). We hypothesized 
that the equipment providing the measurements would not be statistically different. 
METHODS 20 normotensive healthy young adults (20 years +/- 1.1 years) enrolled in this 
study. Subjects were randomly sorted into groups for measurement order. Body composition 
analysis with BodPod was counterbalanced with the Withings Body Cardio scale. Two 
measurements with each operating system were obtained over a period of 30 minutes. 
Standing PWV measurements with SphygmoCor were utilized in order to maintain 
ecological validity with the scale. Three counterbalanced PWV measurements with each 
operating system were obtained over a period of sixty minutes for each individual. All data 
expressed as mean ± SEM. Statistical analysis was performed using two-tailed Student’s t-tests. 
An a priori statistical significance was set at p < 0.05. RESULTS No significant differences 
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were found between body mass measurement between BodPod and Withings Body Cardio 
systems (BMBodPod = 66.6 kg ± 2.6 kg, BMWithings = 66.8 kg ± 2.7 kg, p = 0.000). Significant 
differences were observed in measurement of fat mass (BMBodPod = 8.8 kg ± 1.1 kg, FMWithings = 
11.7 kg ± 1.0 kg, p = 0.003 and fat-free mass (FFMBodPod = 57.9 kg ± 2.7 kg, FFMWithings = 55.0 
kg ± 2.6 kg, p = 0.001). Less than 1 m/s difference was demonstrated between measurements 
with the SphygmoCor and the Withings Body Cardio systems (PWVSphygmoCor = 6.1 m/s 
± 0.1 m/s, PWVWithings = 6.8 m/s ± 0.2 m/s, p = 0.000). CONCLUSION Statistical differences 
between BodPod and the bioelectrical impedance analysis of Withings Body Cardio used to 
measure fat mass and fat-free mass indicate that the Withings system is not accurate for use in a 
clinical setting. There were no clinical differences detected between devices in the measurement 
of PWV, suggesting the home-based system of tracking PWV using the Withings Body Cardio 
can be an accurate measurement of systemic pulse wave velocity. Monitoring cardiopulmonary 
health at home can be useful in providing clinical insight for longitudinal healthcare monitoring. 
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Introduction 
The effects of cardiovascular disease have become increasingly prevalent in the modern 
world. Cardiovascular disease now accounts for over 800,000 deaths annually in the United 
States alone (Benjamin et al., 2017). Cardiovascular disease is composed of a large grouping of 
disease states and is most commonly linked to deleterious change within the major arteries of the 
thorax and heart. The ability to ascertain the health status of the arterial system is crucial to the 
understanding, diagnosis, and monitoring of cardiovascular disease.  
The mechanical properties of healthy arteries serve an important role in the flow of 
blood. During systole, arteries must elicit compliance to increased volume and flow, allowing for 
accommodation of a fluid bolus within the ascending and descending aorta, carotid artery, and 
femoral artery. Through accommodation, adequate coronary and somatic perfusion, as well as the 
management of pressure can be achieved. With aging and disease-related stress, the major 
arteries of the body can experience a significant change in compliance and elasticity, impairing 
vascular function and cardiac performance. This disease process is known as atherosclerosis and 
is characterized by damage to the endothelial lining and intima of the artery. Following damage, 
these lesions are replaced by atherosclerotic plaques formed from calcified and collagenized lipid 
deposits (Palombo and Kozakova, 2015). Plaque buildup is associated with reduced arterial 
compliance and elasticity attributable to increased collagen deposition within the tissue. Over 
time, this buildup can exacerbate disease progression and is associated with a greater risk of 
overall mortality. As previously described, deleterious changes in arterial compliance have been 
shown to be an early risk factor of cardiovascular disease. Pulse wave velocity has been 
cemented as the gold standard for measurement of arterial stiffness and can provide a simple, 
rapid, and non-invasive approach to monitoring of cardiovascular health.  
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This measurement often performed using SphygmoCor (AtCor Medical, Itasca, Illinois, 
USA), is an effective method of determining cardiovascular risk and arterial stiffness. 
Measurement has been proven to be highly reproducible, accurate, and user-friendly. Standard 
procedure includes carotid to femoral measurement through the application of beat-to-beat blood 
pressure monitoring and Doppler ultrasound mediated standard applanation tonometry. Using the 
distance measured between the carotid and femoral sites and the time allotted between pressure 
waveforms, the pulse wave velocity of an individual may be calculated.  
Key to the importance of the measurement of pulse wave velocity is its ability to remove 
much of the white-coat bias present within the assessment of arterial health through the use of 
blood pressure. Within clinical practice, an increased waveform velocity can signify reduced 
arterial compliance, often the result of stenosis, plaque buildup, and general cardiovascular 
disease. These disease properties result in increased aortic pressures, leading to a rapid ejection 
of blood through the arterial system, rather than the gradual accommodation of a fluid bolus, as 
seen within a healthy arterial system. This alteration can significantly increase the strain on the 
heart as a result of increased afterloads applied against contraction, a commonly implicated 
pathway towards advanced stage cardiovascular disease (Zhong et al., 2017).  
 Until recently, the sole methods of measurement of pulse wave velocity required a 
physician or research lab visit. However, with recent advances in healthcare technology, 
Withings has developed a home alternative for the measurement. The Withings Body Cardio 
Scale employs a system of proprietary algorithms to determine a variety of data about an 
individual. This device relies on Wi-Fi to transfer data to a smartphone or website. Unlike the 
SphygmoCor system, which requires a trained operator and clinical visit, the Body Cardio Scale 
is available for personal and individualized home use (Martin et al., 2016).  
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The advantage that the Withings Body Cardio Scale presents in the measurement of an 
individual’s cardiovascular health makes the product extremely desirable in the treatment and 
observation of patients. In addition, the ability of the scale to obtain a clinically accurate 
measurement at the time of waking allows individuals to receive a measurement reflective of 
their true cardiovascular health. This model could be especially beneficial to the general public 
for its ability to obtain measurements in the comfort of an individual’s home without the 
assistance of a presiding healthcare professional. Therefore, the Withings Body Cardio Scale 
could provide a method of at-home observation of patient cardiovascular health for physicians, 
allowing for the application of the technology to clinical practice, in which patients could be 
accessed with the ability to gain day-to-day observation of cardiovascular health. 
In addition to its measurement of pulse wave velocity, the Withings Body Cardio has 
been marketed for its ability to estimate body composition through foot-to-foot bioelectrical 
impedance analysis (BIA). This technology derives body composition, including fat mass and 
fat-free mass through the use of a safe and painless electrical current. The system is far less 
expensive and invasive than alternative forms of analysis such as dual X-ray absorptiometry 
(DEXA), air displacement plethysmography, and water displacement plethysmography (Buffa et 
al., 2014). BIA operates on the principle that the body can be simplified to a cylinder in which 
volume is estimated by length multiplied by cross sectional area. In turn, impedance is inversely 
related to cross sectional area. This principle also assumes homogeneity in material, and hence, 
in conduction. This conduction is made possible by the presence of water in tissue. However, in 
practicality, the body does not possess homogeneity in tissue composition, as various portions of 
the body may be composed of dramatically different levels of fat mass, thereby affecting 
location-specific conductivity (Buffa et al., 2014). In order to combat this problem, BIA now 
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operates via multiple frequencies in order to account for various levels of fluid conductance 
based on the percent water within each solution. Through a set of proprietary algorithms, data 
based on conductance can be used to calculate total body water. According to Kyle, et al. (2004), 
fat-free mass can then be estimated from total body water using the principle that fat mass only 
consists of around seven percent water.  
However, BIA has repeatedly been implicated for a high level of error in measurement. 
This error is commonly attributed to two main culprits. First, the composition of adipocytes can 
vary greatly, especially in the case of perturbations to hydration status, thereby producing 
variance in the amount of total body water stored within the tissue. Secondly, insulating 
properties of adipose tissue deposited within the body can affect the impedance of adjacent fat-
free tissue, thereby producing an erroneously high estimation of fat mass within the body (De 
Lorenzo, Andreoli, Matthie, and Withers, 1997). In a recent study conducted by Buffa, et al. 
(2014), measurement of body composition with BIA was compared to DEXA. It was found to 
produce an increase in percent error of close to nine percent, thereby indicating a 
contraindication to the use of bioelectrical impedance analysis within a clinical setting.  Despite 
previous BIA systems decreased clinical relativity, the Withings Body Cardio scale may provide 
a cheap and effective method of at-home measurement of body composition, therefore increasing 
the relevance of the product.  
 While the Withings Body Cardio has been marketed to the general population for its 
ability to measure pulse wave velocity and body composition at home, there is no data that 
indicates the accuracy of these measures. The purpose of this study was to validate the pulse 
wave velocity and body composition features of the product in a young, healthy population 
through comparison of Withings’ measurements to the gold standards in applanation tonometry 
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and body composition, SphygmoCor and BodPod, respectively. We hypothesized that the 
differences between the gold standards and Withings Body Cardio for pulse wave velocity and 
body composition will not produce statistically different measurements, thereby providing an 
economically affordable and effective method of at-home monitoring.  
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Materials and Methods 
Subject Recruitment and Selection. Subjects were recruited following Appalachian State 
University Review Board (IRB 17-0023) guidelines. A total of twenty subjects (male n = 10, 
female n = 10) were engaged via face to face conversation or through an IRB registered, pre-
approved email. The study was a priori powered using pilot data from our lab with means and 
standard deviation based on pulse wave velocity data. This data demonstrated that a sample size 
of 17 subjects was needed to detect differences at a= 0.8 and p = 0.05. Subjects were of college 
age, between 18 and 25 years old (21.8 years ± 2.0 years), apparently healthy, normotensive, 
with no known disease, and without signs or symptoms of cardiovascular, metabolic, or renal 
disease. All subjects were derived from the student population at Appalachian State University. 
Descriptive characteristics of the subject population are provided within Table 1. Exclusion 
criteria of the study included the presence of chronic disease that might limit participation in 
physical activity or hinder laboratory measurement and the use of the Withings Body Cardio 
scale. Additionally, subjects consuming antihypertensive medications were excluded.  
Pre-Participation Screening. Participants were screened upon arrival for the presence of disease 
or disease symptoms with a medical history form using the Appalachian State University 
Department of Health and Exercise Science Pre-Participation Guidelines. Participants were 
briefed of the study protocol by the investigator in order to gain consent. Following informed 
consent and screening of the pre-participation guidelines, subjects were permitted to enroll in the 
study. Table 1 provides the descriptive characteristics of the subject population included in the 
study.  
 
 Validity of Withings Pulse Wave Velocity Scale 11 
 
Table 1. Subject descriptive data. Subject age (years), height (cm), mass (kg), systolic blood 
pressure (SBP, mm Hg), and diastolic blood pressure (DBP, mm Hg) presented as mean ± 
standard error of the mean (SEM). Descriptive range provided as minimum to maximum. 
Subjects were derived from a young, healthy, and normotensive population.  
  N Minimum Maximum Mean ± SEM 
Age (Years) 20 18 25 21.8 ± 0.44 
Height (cm) 20 160.0 187.3 172.8 ± 1.68 
Mass (kg) 20 51.0 94.5 66.8 ± 2.78 
SBP (mm Hg) 20 126 100 111.2 ± 1.77 
DBP (mm Hg) 20 78 50 63.9 ± 1.43 
Subjects were instructed to report to the Appalachian State University Vascular Biology 
and Autonomic Systems Laboratory (251 Industrial Park Drive Boone, NC 28607) on the 
morning of testing at 8:00 am. Subjects were instructed to refrain from the consumption of food, 
excess fluids, and stimulants in the twelve hours prior to testing. Additionally, subjects were 
instructed to refrain from exercise in the twelve hours of testing. Pre-participation screening and 
informed consent were obtained prior to data collection. Anthropometric data (sex, date-of-birth, 
height, and weight) was collected via the medical history form and a calibrated scale and 
stadiometer. Necessary anthropometric data was inputted into the Withings Health Mate © 
application in order to create a deidentified profile for each subject. This profile was used to 
connect to the Withings Body Cardio Scale, thereby allowing for the ability to monitor the 
scale’s measurement.  
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Blood Pressure Measurement. Following collection of anthropometric data, subjects were 
instructed to be seated upon the examination table for five minutes prior to blood pressure 
measurement. A seated brachial blood pressure measurement was performed by a trained and 
experienced technician according to American Heart Association Guidelines with a medical 
grade stethoscope (Littmann Cardiology III ®, 3M, St. Paul, MN, USA) and sphygmomanometer 
Brachial blood pressure measurement was then repeated utilizing SphygmoCor (AtCor Medical, 
Itasca, Illinois). Subsequently, subjects were randomly assigned to the order of body composition 
analysis and pulse wave velocity measurement.   
Body Composition Analysis. Assessment of body composition was accomplished utilizing whole 
body air displacement plethysmography (BodPod, Life Measurement, Inc., Concord, CA, USA). 
Subjects were instructed to wear compression shorts and an additional sports bra if necessary. 
Height and weight were previously measured using a stadiometer (to the nearest 0.5 cm) and a 
beam balance platform scale. Body mass index was calculated as mass (kg) divided by height 
(m) squared. Body composition was calculated as percent fat mass (%) and percent fat-free mass 
(%). Following body composition analysis with the BodPod, subjects were instructed to step 
onto the Withings Body Cardio (Withings, Issy-les-Moulineaux, France) barefoot. Subjects were 
instructed to remain quiet and still until a successful measurement was confirmed. This protocol 
was repeated for a total of two trials of each system. 
Pulse Wave Analysis. Pulse wave analysis measurements were obtained using the SphygmoCor 
XCEL (AtCor Medical, Itasca, Illinois, USA). Seated brachial blood pressure measurements 
were obtained using the SphygmoCor XCEL. Pulse wave analysis was performed alongside this 
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seated blood pressure measurement, but was not examined within this comparative study, as the 
Withings system does not produce this data.  
Pulse Wave Velocity Measurement. Carotid-femoral pulse wave velocity measurements were 
obtained using SphygmoCor XCEL. Measurement was performed by a trained technician. The 
subject was instructed to stand barefoot within range of the SphygmoCor system. Standing 
brachial blood pressure assessment was performed after the subject had stood at rest for three 
minutes.  The femoral sphygmomanometer cuff was placed around the right thigh. Measurement 
(in cm) of aortic length was approximated manually with a basic tape measure. This was 
accomplished by palpation of carotid pulse and estimation of femoral bifurcation, measurement 
of carotid artery to sternal notch, sternal notch to cuff, and femoral bifurcation to cuff. 
Measurement of pulse wave velocity was performed while upright, in order to replicate the 
conditions present when using the Withings Body Cardio, by applanation tonometry via 
palpation of the carotid artery with a doppler pen.  
 Following measurement of pulse wave velocity with the SphygmoCor system, the subject 
was instructed to step onto the Withings Body Cardio scale. The subject remained on the scale 
until a successful measurement of pulse wave velocity was confirmed. This protocol was 
repeated an additional two times in order to obtain a total of three measurements with each 
system.  
Statistical Analysis. Data was collected from the BodPod, SphygmoCor, and Withings Health 
Mate © application. Average value of each measurement and standard error of the mean was 
calculated and used for subsequent analysis. Statistical analysis relied on IBM SPSS version 14 
(SPSS Inc., Chicago, IL, USA).  Bland-Altman analysis was utilized to analyze pulse wave 
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velocity and body composition data. Bias was calculated as the criterion-reference measurement 
minus the General Wellness Product measurement. A two-tailed Student’s t-tests were performed 
to calculate the mean difference and 95 % confidence intervals of the data. These intervals were 
used to create the Bland-Altman plots. Regression analysis was performed to evaluate for 
proportional bias and Pearson correlation coefficient. Mean Absolute Percent Error (MAPE) 
presents the error as a percentage of the overall mean and indicates the degree of error. 
Additionally, repeated measures ANOVA was conducted to analyze variance attributable to sex 
difference between devices. An a priori significance of p < 0.05 was utilized.  
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Figure 1. Study design and protocol. Subjects were screened and informed consent was given. 
Body composition analysis and pulse wave velocity measurement performed. Statistical analysis 
performed with an a priori significance of p < 0.05.  
Blood Pressure Assessment 
• Manual resting BP 
• SBP: 111.2 mm Hg ± 7.9 mm Hg 
• DBP: 63.9 mm Hg± 6.4 mm Hg 
• Random group assignment 
Body Composition Analysis 
• Height and weight obtained 
• 2 accepted trials with each system 
• Counterbalanced trials 
Pulse Wave Velocity 
• Pulse wave analysis performed to 
obtain second BP measure 
• 3 accepted trials with each system 
• Counterbalanced trials 
 
 
BodPod 
 
 
Withings Body 
Cardio 
 
 
SphygmoCor 
 
 
Withings Body 
Cardio 
 
Statistical Analysis 
• Average value and standard error of mean obtained 
• Bland-Altman Analysis, 95 % confidence interval 
• Mean difference and MAPE calculated with Student’s t-test 
• ANOVA utilized to explore sex differences 
Subject Recruitment and Pre-Participation Screening 
• Subjects obtained through word of mouth 
• Young, healthy, normotensive 
• N = 20, Age = 21.8 years ± 2.0 years 
• Screened for presence of disease, hypertensive medication 
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Results 
Body Composition Analysis. Body composition analysis of the Withings Body Cardio was 
compared with BodPod. Measurement of body mass, fat mass, and fat-free mass in kilograms are 
presented as mean ± standard error of the mean in Table 2. Data is presented by sex, as well as 
by a total measurement. A graphical representation for the measurement of body mass is 
presented within Figure 2. Significant differences in the measurement of body mass, p = 0.000, 
were obtained between systems. The mean difference in body mass between the two systems was 
calculated to be 0.2 kg with a confidence interval of -0.41 and 0.18, respectively, as shown in 
Figure 3. Regression analysis produced a Pearson correlation coefficient of 0.47 with an 
evidence of proportional bias (p < 0.05). Analysis of variance (ANOVA) showed no effect of sex 
on body mass measurement between systems. Mean absolute percent error (MAPE) was 
determined to be 0.15 %.  
 The measurement of fat mass between systems is graphically represented in Figure 4 as 
mean ± standard error of the mean. Significant differences in the measurement of fat mass, p = 
0.003, were obtained between systems. The mean difference in the measurement of fat mass was 
determined to be 2.91 kg with a confidence interval of -2.91 and 8.73, respectively, as shown in 
Figure 5. Regression analysis of the fat mass measurement data produced a Pearson correlation 
coefficient of 0.16 and no evidence of proportional bias. Analysis of variance (ANOVA) 
indicated that sex differences had no effect on the measurement of fat mass between devices. 
MAPE was calculated to be 25.8 %.  
 The measurement of fat-free mass between systems is graphically represented in Figure 6 
as mean ± standard error of the mean. Significant differences in the measurement of fat-free 
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mass, p = 0.001, were determined between systems. The mean difference in the measurement of 
fat-free mass was determined to be 2.87 kg with a confidence interval of -9.04 and 3.30, 
respectively, as shown in Figure 7. Regression analysis of the fat-free mass measurement data 
produced a Pearson correlation coefficient of 0.06 and no evidence of proportional bias. Analysis 
of variance (ANOVA) indicated no effect of sex on fat-free mass measurement between the 
Withings Body Cardio and BodPod systems. MAPE was calculated to 5.6 %.  
Table 2. Body composition data of Withings and BodPod. Data presented as mean ± SEM. BM = 
Body Mass, FM = Fat Mass, FFM = Fat-Free Mass. Significant differences were measured 
across all values.  
 Body Mass (kg) Fat Mass (kg) Fat-Free Mass (kg) 
Withings 66.8 ± 2.7 11.7 ± 1.0 55.0 ± 2.6 
BodPod 66.6 ± 2.6 8.8 ± 1.1 57.9 ± 2.7 
P Value 0.000 0.003 0.001 
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Figure 2. Mean body mass measurement by Withings and BodPod systems. Data not 
differentiated by sex. Data presented by mean ± SEM. BMWithings = 66.8 kg ± 2.7 kg. BMBodPod = 
66.6 ± 2.6 kg. P = 0.000.  
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Figure 3. Mean difference with 95 % confidence intervals of body mass measurement between 
Withings and BodPod.  
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Figure 4. Mean fat mass measurement by Withings and BodPod systems. Data not differentiated 
by sex. Data presented by mean ± SEM. FMWithings = 11.7 kg ± 1.0 kg.  FMBodPod = 8.8 ± 1.1 kg. P 
= 0.003. 
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Figure 5. Mean difference with 95 % confidence intervals of fat mass measurement between 
Withings and BodPod.  
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Figure 6. Mean fat-free mass measurement by Withings and BodPod systems. Data not 
differentiated by sex. Data presented by mean ± SEM. FFMWithings = 55.0 kg ± 2.6 kg. FFMBodPod 
= 57.9 ± 2.7 kg. P = 0.001.  
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Figure 7. Mean difference with 95 % confidence intervals of fat-free mass measurement 
between Withings and BodPod.  
Pulse Wave Velocity Measurement. Pulse wave velocity measurement of the Withings Body 
Cardio was compared with the gold standard SphygmoCor. Measurement of pulse wave velocity 
and heart rate by device are presented as mean ± standard error of the mean in Table 3. Data is 
presented by sex, as well as by a total measurement. No significant differences were determined 
in the measurement of heart rate between systems, p = 0.681. A graphical representation for the 
measurement of pulse wave velocity as mean ± standard error of the mean is presented within 
Figure 8. Significant statistical differences in the measurement of pulse wave velocity, p= 0.000, 
were obtained between systems. The mean difference in pulse wave velocity between the two 
systems was calculated to be 0.68 m/s with a confidence interval of -0.16 and 1.51 respectively, 
as shown in Figure 9. Regression analysis produced a Pearson correlation coefficient of 0.49 
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with an evidence of proportional bias (p < 0.05). Analysis of variance (ANOVA) showed no 
effect of sex on body mass measurement between systems. MAPE was determined to be 9.7 %. 
Table 3. Mean pulse wave velocity and heart rate measurement between Withings and 
SphygmoCor systems. Data presented as mean ± SEM. PWV= pulse wave velocity (m/s) 
 
 
Figure 8.  Mean pulse wave velocity measurement by Withings and BodPod systems. Data not 
differentiated by sex. Data presented by mean ± SEM. PWVWithings = 6.1 m/s ± 0.1 m/s. 
PWVBodPod = 6.8 m/s ± 0.1 m/s. P = 0.000 
 
 PWVWithings (m/s) PWVSphygmoCor (m/s) HRWithings (bpm) HRSphygmoCor (bpm) 
Total 6.1 ± 0.1 6.8 ± 0.1 73.1 73.5 
P Value 0.000 0.681 
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Figure 9. Mean difference and 95 % confidence intervals of pulse wave velocity between 
Withings and SphygmoCor.  
Individual systolic blood pressure measurements obtained manually were compared to 
the same subject’s standing pulse wave velocity measurements obtained with the SphygmoCor 
system. A linear regression analysis was performed and generated an R2 correlation of 0.1179, 
suggesting a minimal relationship within the data. Graphical representation of the linear 
regression analysis can be found in Figure 10. Subsequently, a second linear regression analysis 
(Figure 11) was performed to analyze the correlation between systolic blood pressure and 
Withings Body Cardio pulse wave velocity measurements. An R2 correlation of 0.01208 was 
obtained, suggesting an extremely minimal relationship between the Withings PWV 
measurement and systolic blood pressure.  
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Figure 10. Comparison of SphygmoCor pulse wave velocity measurement to systolic blood 
pressure. Data not differentiated by sex. R2 Correlation = 0.1179. 
 
Figure 11. Comparison of Withings pulse wave velocity measurement to systolic blood pressure. 
Data not differentiated by sex.  R2 Correlation = 0.01208.   
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Discussion 
 The use of personal health devices, such as activity trackers, scales, and mobile phone 
health and fitness applications has increased significantly in the last decade. These tools provide 
a simple, user-friendly method of at-home monitoring of personal health and fitness. The 
Withings Body Cardio scale is part of a new generation of health devices that provide detailed 
information beyond a simple step counter or heart rate monitor. The purpose of this study was to 
compare Withings’ measurements of body composition analysis and pulse wave velocity to gold 
standards in the field.  
Body Composition Analysis. Comparison of body composition measurement and analysis 
between the Withings Body Cardio scale and the BodPod, the gold standard in air displacement 
plethysmography, yielded no significant difference in the measurement of body mass. Mean 
difference was a mere 0.2 kg with a MAPE of 0.15 %, well within the error limit or 1.5 % as set 
by Ball and Altena in their comparison of BodPod and DEXA body composition analysis (2004). 
The similarity in the two measurements can be attributed to the method of mass sampling and is 
reflected within the Bland-Altman analysis in Figure 3. Variance in measurement does persist, 
however it lies within the confidence interval set. Most electric bathroom scales now rely on 
sampling of strain in order to determine mass. This method of measurement of body mass is 
relatively simple in comparison to measurement of body composition through bioelectrical 
impedance, which may point to the higher percent error in these measurements.  
 Sampling of fat mass between devices produced a mean difference in measurement of 
2.91 kg with a MAPE of 25.8 %. This MAPE is well above the error limit of 1.5 % set by Ball 
and Altena, thereby indicating that analysis of fat mass with Withings BIA system is not 
accurate. In addition, measurement of fat-free mass produced a mean difference of measurement 
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of 2.87 kg with a MAPE of 5.6 %. While estimation of fat-free mass was more accurate than 
estimation of fat mass, it still falls outside of the excepted error range. For this reason, the 
Withings Body Cardio’s measurement of body composition cannot be accepted as accurate in 
comparison to gold standard air displacement plethysmography.  
One of the main sources of error in Withings Body Cardio may be the use of bioelectrical 
impedance as a source of measurement. This system relies heavily upon proper hydration in 
order to determine body composition. If subjects were inadequately hydrated, whether being 
under or over hydrated, significant alterations in current flow could have been produced. During 
this study, hydration status was not closely monitored, rather individuals were instructed to 
refrain from the consumption of excess fluids. While this could have contributed to a main 
source of error within the study, the protocol also reflects the day-to-day changes present in 
hydration status for individuals. The Withings Body Cardio is marketed as a method of at-home 
measurement of body composition analysis, in which the algorithm would be exposed to a large 
range of hydration status fluctuations. These common fluctuations in hydration further support 
the conclusion that Withings’ use of bioelectrical impedance as a method of body composition 
analysis is not accurate for at-home measurement, as the system is unable to account and 
standardize for these alterations in current flow.  
Pulse Wave Velocity Measurement. The Withings Body Cardio scale was compared with the gold 
standard in the determination pulse wave velocity through applanation tonometry, SphygmoCor, 
in order to determine the accuracy of the Withings measurement. The mean difference between 
the two systems was calculated to be 0.68 m/s with a mean percent error of 9.7 %. While error is 
present, the ARTERY Society, a leading source on the measurement of arterial health, states that 
an “acceptable” clinical accuracy rating in the measurement of pulse wave velocity may not 
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exceed a mean difference greater than 1.0 m/s and a standard deviation of 1.5 m/s (Clinical Task 
Force for Pulse Wave Velocity v3). While previous data examined the mean ± the standard error 
of the mean, providing a mean difference of 0.7 m/s, the standard deviation of the Withings pulse 
wave velocity measurement was calculated to be 0.57 m/s, well within the acceptable range 
stated by the ARTERY Society.  
Overall, data collected with the two devices indicates that the Withings Body Cardio 
scale is capable of providing an affordable, acceptably accurate, and reproducible measurement 
of pulse wave velocity. The Withings Body Cardio system may provide an economic and readily 
available method of at-home monitoring of cardiovascular and arterial health. The scale, when 
paired with Withings’ Health Mate © phone application or website, allows for both detailed 
historical storage and simplified presentation of data, thereby providing users with an 
opportunity to track arterial health over time. While not yet verified for accuracy in clinical 
populations, the Withings Body Cardio and Health Mate © application could provide physicians 
with a new method of patient monitoring, allowing for detailed tracking of disease progression 
and treatment. The ability of the Withings Body Cardio to aid in the prediction of cardiovascular 
disease-related complications through the system’s pulse wave velocity measurement strengthens 
the importance of these findings.  
While a previous study (Campo, et al., 2017) has already observed and described the 
accuracy of the pulse wave velocity measurement of the Withings Body Cardio, key flaws in 
study design limited conclusions on the accuracy of the device. Most importantly, Campo, et al. 
compared the standing Withings Body Cardio pulse wave velocity measurement to SphygmoCor 
measurement in the supine position. It is well known that gravity is a major contributor to 
alterations in pulse wave velocity; heart mechanics become significantly altered under decreased 
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afterload and increased venous return within a supine state. Ultimately the data produced 
between the devices was not comparable, as Withings’ algorithm did not take into account the 
alterations in pulse wave velocity due to postural differences. In contrast, this study sought to 
elucidate the true accuracy of the Withings Body Cardio through comparison of pulse wave 
velocity measurement in the same posture. Again, the measurement of pulse wave velocity 
calculated by the Withings Body Cardio system was found to be acceptably accurate. 
Limitations and Future Direction.  This study was completed within a small cohort of college-
aged, apparently healthy individuals. While a total of twenty subjects, ten males and ten females, 
were recruited and sampled for data collection, variance due to sex differences may have 
produced error in analysis. This small sample size also limits the impact of the study, as the 
relatively small sample size could have hidden proportional bias necessary to determine 
sensitivity. As stated previously, hydration status was also not controlled tightly, which may have 
led to error attributable to water content in the measurement of body composition using the 
Withings Body Cardio scale. Possible future directions of the study include analysis of the 
Withings Body Cardio pulse wave velocity measurement in elderly and clinical populations, such 
as those suffering from cardiovascular, pulmonary, renal, or metabolic disease. Validation of the 
pulse wave velocity measurement could produce significant impacts in the clinical setting. In 
recent studies within Chinese clinical populations, the use of health applications significantly 
impacted positive patient incomes, highlighting the relevance of this technology in the 
management and treatment of disease (Lu et al., 2018). Additional investigation is needed to 
determine the health benefits associated with the use of the Withings Health Mate © application.  
Conclusion. The Withings Body Cardio scale provides users with a variety of useful health 
information. The system’s online application allows for user-friendly monitoring of health 
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progress. That said, this study highlighted inaccuracies in the device’s determination of body 
composition through measurement of fat mass and fat-free mass. Ultimately, the system’s 
reliance on bioelectrical impedance to calculate composition is grossly inaccurate. In contrast, 
the Withings system did produce an acceptable level of accuracy, well within the ARTERY 
Society’s general guidelines. The Withings Body Cardio may supply an accurate and affordable 
method of at-home monitoring of arterial health.  
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